68Ga-FAPI-46 PET/CT在胃SMARCA4缺陷未分化癌转移灶识别中优于18F-FDG PET/CT一例
本文报告一例胃SMARCA4缺陷未分化癌患者的18F-FDG与68Ga-FAPI-46 PET/CT显像表现。68Ga-FAPI-46 PET/CT对原发肿瘤的肿瘤-本底对比度更高,并较18F-FDG PET/CT显示更多转移灶。该病例显示68Ga-FAPI PET/CT在识别SMARCA4缺陷未分化癌原发及转移灶方面优于18F-FDG。
要点
- 胃SMARCA4缺陷未分化癌为SMARCA4失活、生长迅速且预后差的新临床实体。
- 68Ga-FAPI-46 PET/CT对原发肿瘤的肿瘤-本底对比度高于18F-FDG PET/CT。
- 68Ga-FAPI-46 PET/CT较18F-FDG PET/CT显示更多转移灶。
核心结论
- 本病例显示68Ga-FAPI PET/CT在识别SMARCA4缺陷未分化癌原发及转移灶方面优于18F-FDG PET/CT。
- 作者认为这一观察可能为FAPI PET在肿瘤影像中的获益增添信息。
研究设计与样本
- 本文为个案报告,报告一例胃SMARCA4缺陷未分化癌患者的18F-FDG与68Ga-FAPI-46 PET/CT显像表现。
主要发现
- 68Ga-FAPI-46 PET/CT对原发肿瘤的肿瘤-本底对比度明显高于18F-FDG PET/CT。
- 68Ga-FAPI-46 PET/CT较18F-FDG PET/CT显示更多转移灶。
临床怎么用
- 作者认为68Ga-FAPI PET/CT在识别SMARCA4缺陷未分化癌原发及转移灶方面优于18F-FDG PET/CT,可能为FAPI PET在肿瘤影像中的获益增添信息。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SMARCA4-deficient undifferentiated carcinoma is a new clinical entity characterized by SMARCA4 inactivation and has a dismal prognosis because of rapid growth. In this case, we reported 18 F-FDG and 68 Ga-FAPI-46 PET/CT imaging findings in a patient with SMARCA4-deficient undifferentiated carcinoma of stomach. 68 Ga-FAPI-46 PET/CT showed much higher tumor-to-background contrast of primary tumor and revealed more metastatic lesions than 18 F-FDG PET/CT. This case demonstrated the superiority of 68 Ga-FAPI PET/CT over 18 F-FDG for identifying both primary and metastatic lesions in SMARCA4-deficient undifferentiated carcinoma. This observation may add the information on the benefit of FAPI PET in oncology imaging.
引用
- Pang Y, Cai J, Zhao L, et al. Superior Identification of Metastatic Lesions by 68 Ga-FAPI-46 to 18 F-FDG PET/CT in a Case of SMARCA4-Deficient Undifferentiated Carcinoma of Stomach. Clin Nucl Med. 2023. PMID: 37703493. doi:10.1097/RLU.0000000000004860
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。